文献速递免疫规划传染病防控与疫情报告

健康菲律宾成人与儿童接种至少一剂Vi-DT疫苗后5年免疫应答的持久性

Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children.
PubMed 文献 · Vaccine · 2025-09-16

本研究为一项在菲律宾开展的I期临床试验的长期观察性随访,对曾接种至少一剂Vi-DT疫苗或Vi多糖疫苗的2-45岁健康人群在接种后第3、4、5年采集血样,评估抗Vi IgG和血清杀菌抗体(SBA)的持久性。结果显示Vi-DT组抗Vi IgG血清转化率在各年龄层均较高,第3年98.44%(95%CI:91.67,99.72)、第4年100.00%(95%CI:94.08,100.00)、第5年98.41%(95%CI:91.54,99.72),抗Vi IgG GMT在各年龄层也均较高。Vi-DT疫苗可提供至少5年免疫,但5年以上的数据对判断是否需要加强剂仍有价值。

要点

  • Vi-DT组抗Vi IgG血清转化率第3年98.44%、第4年100.00%、第5年98.41%。
  • Vi-DT组抗Vi IgG GMT在各年龄层均较高。
  • Vi-DT组18-45岁人群SBA血清转化率第3年75.00%、第4年86.67%、第5年60.00%。

核心结论

  • Vi-DT疫苗在接种后至少5年内可提供免疫。
  • 5年以上的数据对判断是否需要加强剂仍有价值。

研究设计与样本

  • 研究为观察性研究,随访参加I期临床试验并接种Vi-DT疫苗或对照Vi多糖疫苗的2-45岁健康菲律宾成人与儿童,至入组后5年。
  • 纳入至少接种一剂任一疫苗并同意提供至少一份血样的参与者。
  • 于接种后第3年、第4年、第5年三个时间点采集血样,检测抗Vi IgG和血清杀菌抗体(SBA)。
  • 2019年10月30日至2022年1月13日期间,从137名接种至少一剂Vi-DT或Vi多糖疫苗的参与者采集了接种后3年的血样。

主要发现

  • Vi-DT组抗Vi IgG血清转化率在各年龄层均较高:第3年98.44%(95%CI:91.67,99.72),第4年100.00%(95%CI:94.08,100.00),第5年98.41%(95%CI:91.54,99.72)。
  • Vi-DT组抗Vi IgG GMT在各年龄层也均较高。
  • Vi-DT组18-45岁人群SBA血清转化率第3年75.00%(95%CI:50.50,89.82),第4年86.67%(95%CI:62.12,96.26),第5年60.00%(95%CI:35.75,80.18)。

关键数值与推荐

  • Vi-DT组抗Vi IgG血清转化率第3年98.44%(95%CI:91.67,99.72)、第4年100.00%(95%CI:94.08,100.00)、第5年98.41%(95%CI:91.54,99.72)。
  • Vi-DT组18-45岁人群SBA血清转化率第3年75.00%(95%CI:50.50,89.82)、第4年86.67%(95%CI:62.12,96.26)、第5年60.00%(95%CI:35.75,80.18)。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Typhoid Conjugate Vaccine (TCV) has been shown to elicit robust immune responses among adults and children. However, data on long-term immunogenicity are sparse. The International Vaccine Institute has conducted a Phase I clinical trial in The Philippines to investigate safety and immunogenicity among healthy individual 2-45 years old. In this study we present the results of a long-term immunogenicity study - 5 years after a typhoid conjugate vaccine composed of Vi polysaccharide conjugated to diphtheria toxoid (Vi-DT) and Vi-polysaccharide vaccine was administered. In this observational study, we followed up the participants who were vaccinated by either the Vi-DT vaccine or comparator vaccine, the Vi-polysaccharide vaccine, for five years after the enrollment in the phase I study. We assessed the safety and immunogenicity of the Vi-DT vaccine among healthy Filipino adults and children, aged 2-45 years and compared it descriptively to a Vi polysaccharide vaccine. Participants who had received at least one dose of either vaccine and agreed to provide at least one blood sample were enrolled to the study. Blood samples were collected to assess the longevity of immunity using anti-Vi IgG and serum bactericidal antibody (SBA) at three different time points: 3 years, 4 years, and 5 years after the vaccination. Between 30 October 2019 and 13 January 2022, blood samples were collected from 137 participants who had received at least one dose of Vi-DT or Vi polysaccharide vaccine, 3 years post-vaccination. Anti-Vi IgG seroconversion of Vi-DT vaccinees was higher in all age strata; 98.44 % (95 % confidence interval (CI): 91.67, 99.72) at year 3, 100.00 % (95 % CI: 94.08, 100.00) at year 4 and 98.41 % (95 % CI: 91.54, 99.72) at year 5. Anti-Vi IgG GMT was higher in the Vi-DT group among all age strata as well. Seroconversion by SBA in the Vi-DT group was higher in the 18-45 age group calculating 75.00 % (95 % CI: 50.50, 89.82), 86.67 % (95 % CI: 62.12, 96.26), and 60.00 % (95 % CI: 35.75, 80.18) at 3rd, 4th and 5th year post-vaccination, respectively. The Vi-DT vaccine provides immunity for at least five years after vaccination. However, data beyond 5 years would be valuable to inform the need for booster doses.

来源:Vaccine,查看原文。版权归原作者所有。

引用

  1. Pial RH, Capeding MR, Tadesse BT, et al. Longevity of immune-response provided by at least one dose of vi-DT vaccine 5 years after vaccination among healthy Filipino adults and children. Vaccine. 2025. PMID: 40961798. doi:10.1016/j.vaccine.2025.127751

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。